
MALAYSIA

EPIDEMIC ESTIMATES			
	2010	2015	2019
New HIV infections			
New HIV infections (all ages)	5400	5200	6300
	[4900–5900]	[4700–5700]	[5500–7100]
New HIV infections (0-14)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
New HIV infections (women, 15+)	1000	720	580
	[870–1100]	[620–800]	[<500–690]
New HIV infections (men, 15+)	4300	4500	5700
	[3900–4700]	[4000–4900]	[5000–6400]
IIV incidence per 1000 population	0.19 [0.18–0.21]	0.17 [0.15–0.19]	0.2 [0.18–0.23]
AIDS-related deaths			
IDS valeted deethe (all exce)	2900	3500	2700
IDS-related deaths (all ages)	[2300–3400]	[3000–4100]	[2100–3400]
IDS related deaths (0, 44)	<100	<100	<100
AIDS-related deaths (0-14)	[<100-<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<500	<500
NDS-related deaths (wollien, 15+)	[<200-<500]	[<500–600]	[<500–510]
	2500	3000	2300
AIDS-related deaths (men, 15+)	[2100–3000]	[2600–3500]	[1900–2800]
eople living with HIV			
People living with HIV (all ages)	71 000	78 000	88 000
reopie livilig with filv (all ages)	[61 000–83 000]	[69 000–89 000]	[78 000–98 000]
People living with HIV (0-14)	<500	<500	<500
reopie living with filv (0-14)	[<500–580]	[<500–530]	[<500-<500]
eople living with HIV (women, 15+)	12 000	15 000	15 000
reopie livilig with file (wonten, 15+)	[11 000–14 000]	[13 000–16 000]	[14 000–17 000]
People living with HIV (man 15±)	58 000	63 000	72 000
People living with HIV (men, 15+)	[50 000–69 000]	[56 000–72 000]	[64 000–81 000]
IV prevalence (15–49)	0.4 [0.3–0.5]	0.4 [0.3–0.4]	0.4 [0.4–0.4]

EPIDEMIC TRANSITION METRICS




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 607 630	US\$ 23 214 913	US\$ 0	US\$ 487 627	US\$ 40 342	US\$ 24 360 560

Note: Global AIDS Monitoring report was not available at the time of publication.

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



All ages	89% [79–100%]	50% [45–56%] 44 168	% [–%]
Children (0–14)	92% [77–100%]	92% [77–100%] 301	% [%]
Women (15+)	74% [66–83%]	71% [63–79%] 10 679	% [%]
Men (15+)	92% [82–100%]	46% [41–52%] 33 188	% [–%]

FLIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2019
Percentage of pregnant women living with HIV	79%	100%
accessing antiretroviral medicines	[66–92%]	[84–100%]
Final vertical transmission rate including during	17%	2%
breastfeeding	[15–19%]	[1–2%]
Early infant diagnosis	76.1%	95.0%
Larry Illiant diagnosis	[65.2-90.8%]	[82.9->95%]